Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.83 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506072 | 0.91 | ADORA2A (0.84) | ADORA2AADORA1 | |
| SCHEMBL13966227 | 0.91 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL4530247 | 0.91 | ADORA2A (0.83) | ADORA2AADORA1 | |
| SCHEMBL14569039 | 0.91 | ADORA2A (0.82) | ADORA2AADORA1 | |
| SCHEMBL13966143 | 0.88 | ADORA2A (0.88) | ADORA2AADORA1 | |
| SCHEMBL4522379 | 0.88 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL4515952 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL13966104 | 0.86 | ADORA2A (0.86) | ADORA2AADORA1 | |
| SCHEMBL13966173 | 0.86 | ADORA2A (1.00) | ADORA2AADORA1 | |
| SCHEMBL13966229 | 0.86 | ADORA2A (0.74) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035873-A1 | PURINONE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023723-A1 | Purinone derivatives for treating neurodegenerative diseases | ADORA2A, P2RX6, P2RX5 | ADORA2A 1/4885ADORA1 9/4885CDK1 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.